Molly Henderson - 31 Jan 2022 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Financial Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
31 Jan 2022
Net transactions value
-$2,509
Form type
4
Filing time
02 Feb 2022, 15:34:38 UTC
Previous filing
02 Dec 2021
Next filing
06 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +666 +14% 5,579 31 Jan 2022 Direct F1
transaction URGN Ordinary Shares Sale $2,509 -331 -5.9% $7.58 5,248 31 Jan 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -666 -33% $0.000000 1,334 31 Jan 2022 Ordinary Shares 1,334 Direct F1, F3
transaction URGN Restricted Stock Units Award $0 +7,500 $0.000000 7,500 31 Jan 2022 Ordinary Shares 7,500 Direct F1, F4
transaction URGN Stock Option (right to buy) Award $0 +30,000 $0.000000 30,000 31 Jan 2022 Ordinary Shares 30,000 $7.72 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
F3 The reporting person was granted RSUs on January 31, 2021 representing 2,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022.
F4 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025.
F5 1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025.